Immutep Ltd ADR (IMMP)

$1.74 +0.02 (1.16%)
Market Cap 251.19M
Revenue (ttm) 5.14M
Net Income (ttm) -28.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -544.94%
Debt to Equity Ratio 0.01
Volume 28,100
Avg Vol 88,886
Day's Range N/A - N/A
Shares Out 146.04M
Stochastic %K 44%
Beta 1.66
Analysts Strong Sell
Price Target $9.50

Company Profile

Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 2 8315 7003
Fax: 61 2 8569 1880
Address:
Australia Square, Level 32 264 George Street, Sydney, Australia
SeatownGreen
SeatownGreen Aug. 5 at 1:54 PM
$IMMP It’s always come down to the partnership Immutep consummates. There’s an exciting implication in this HNSCC single arm pathway discussed with FDA. It really applies to all 18 approved Keytruda indications with zero PD-L1 expression. Also applies to other PD-1/PD-L1 therapies, which are many. The development deal is where this has always been headed.
0 · Reply
brad97
brad97 Aug. 5 at 1:52 PM
$IMMP
0 · Reply
rispi
rispi Aug. 5 at 1:46 PM
$IMMP
0 · Reply
Nico07
Nico07 Aug. 5 at 1:33 PM
$IMMP The clue of the story is nobody knows 🫣 Let’s go Immutep
0 · Reply
gloryb
gloryb Aug. 5 at 12:57 PM
$IMMP well that was fun for 30 minutes
0 · Reply
MasterOfMyDomains
MasterOfMyDomains Aug. 5 at 12:10 PM
$IMMP https://www.stocktitan.net/news/IMMP/immutep-receives-positive-feedback-from-fda-on-late-stage-clinical-qk17pahwvxqx.html
0 · Reply
MasterOfMyDomains
MasterOfMyDomains Aug. 5 at 12:06 PM
$IMMP
0 · Reply
dbr_island
dbr_island Aug. 5 at 12:02 PM
$IMMP lnow VYNE very soon 🧨 Here’s why👇
0 · Reply
Stock_Catcher
Stock_Catcher Aug. 5 at 12:01 PM
$IMMP hits
0 · Reply
theinvestaar
theinvestaar Aug. 5 at 2:35 AM
$IMMP you don't even make sense what you're talking about. How many presentations do we have coming up at ESMO?
2 · Reply
Latest News on IMMP
Immutep Quarterly Activities Report Q4 FY25

Jul 30, 2025, 8:00 AM EDT - 6 days ago

Immutep Quarterly Activities Report Q4 FY25

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

Jul 29, 2025, 8:00 AM EDT - 7 days ago

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

May 27, 2025, 8:00 AM EDT - 2 months ago

Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo

May 15, 2025, 3:50 PM EDT - 2 months ago

Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo

Immutep Limited: Surging On Positive Head And Neck Data

May 8, 2025, 8:46 AM EDT - 3 months ago

Immutep Limited: Surging On Positive Head And Neck Data

Immutep to Participate in Upcoming Investor Conferences

Apr 2, 2025, 8:00 AM EDT - 4 months ago

Immutep to Participate in Upcoming Investor Conferences

Immutep Quarterly Activities Report Q2 FY25

Jan 31, 2025, 8:00 AM EST - 6 months ago

Immutep Quarterly Activities Report Q2 FY25

Immutep Limited: Continuing To Make The Case For Eftilagimod

Jan 28, 2025, 4:37 PM EST - 6 months ago

Immutep Limited: Continuing To Make The Case For Eftilagimod

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Dec 17, 2024, 8:00 AM EST - 8 months ago

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Dec 12, 2024, 8:15 AM EST - 8 months ago

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients

Nov 15, 2024, 3:18 PM EST - 9 months ago

Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients

Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial

Nov 14, 2024, 11:16 AM EST - 9 months ago

Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial

Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Nov 14, 2024, 8:15 AM EST - 9 months ago

Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Immutep Quarterly Activities Report Q1 FY25

Oct 29, 2024, 8:00 AM EDT - 10 months ago

Immutep Quarterly Activities Report Q1 FY25

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 10, 2024, 8:00 AM EDT - 10 months ago

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

Immutep: Navigating The Bumps In The Road

Oct 7, 2024, 9:10 AM EDT - 10 months ago

Immutep: Navigating The Bumps In The Road

Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

Sep 16, 2024, 8:00 AM EDT - 11 months ago

Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

Immutep Quarterly Activities Report Q4 FY24

Jul 31, 2024, 8:00 AM EDT - 1 year ago

Immutep Quarterly Activities Report Q4 FY24

Immutep: Positive Efti Treatment Data Leads To Late-Stage Programs

Jul 15, 2024, 1:54 PM EDT - 1 year ago

Immutep: Positive Efti Treatment Data Leads To Late-Stage Programs

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

Jul 11, 2024, 6:40 PM EDT - 1 year ago

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

Jul 3, 2024, 8:00 AM EDT - 1 year ago

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

Jun 25, 2024, 8:00 AM EDT - 1 year ago

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

Immutep successfully completes institutional placement and institutional component of entitlement offer

Jun 5, 2024, 6:00 AM EDT - 1 year ago

Immutep successfully completes institutional placement and institutional component of entitlement offer

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

Jun 2, 2024, 8:38 PM EDT - 1 year ago

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

May 15, 2024, 8:00 AM EDT - 1 year ago

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

May 2, 2024, 8:00 AM EDT - 1 year ago

Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Immutep: Realizing The Expected Catalysts, With More To Come

May 1, 2024, 12:39 PM EDT - 1 year ago

Immutep: Realizing The Expected Catalysts, With More To Come

Immutep Quarterly Activities Report Q3 FY24

Apr 29, 2024, 8:00 AM EDT - 1 year ago

Immutep Quarterly Activities Report Q3 FY24

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Apr 24, 2024, 8:00 AM EDT - 1 year ago

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Apr 18, 2024, 8:00 AM EDT - 1 year ago

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Apr 17, 2024, 8:00 AM EDT - 1 year ago

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Mar 5, 2024, 8:00 AM EST - 1 year ago

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Immutep Quarterly Activities Report Q2 FY24

Jan 30, 2024, 8:00 AM EST - 1 year ago

Immutep Quarterly Activities Report Q2 FY24

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Jan 4, 2024, 8:00 AM EST - 1 year ago

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Immutep: Upcoming Signals For 2024 (Maintain Buy)

Jan 3, 2024, 5:04 PM EST - 1 year ago

Immutep: Upcoming Signals For 2024 (Maintain Buy)

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Dec 21, 2023, 8:00 AM EST - 1 year ago

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Dec 7, 2023, 8:00 AM EST - 1 year ago

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

Nov 22, 2023, 8:00 AM EST - 1 year ago

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Nov 9, 2023, 8:00 AM EST - 1 year ago

Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer

Nov 6, 2023, 8:00 AM EST - 1 year ago

Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer

Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer

Nov 3, 2023, 12:00 PM EDT - 1 year ago

Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer

Immutep to Participate in November Investor Events

Nov 2, 2023, 8:00 AM EDT - 1 year ago

Immutep to Participate in November Investor Events

Immutep Quarterly Activities Report Q1 FY24

Oct 31, 2023, 8:00 AM EDT - 1 year ago

Immutep Quarterly Activities Report Q1 FY24

Immutep receives ~A$1.13 million R&D Tax Incentive

Oct 25, 2023, 8:00 AM EDT - 1 year ago

Immutep receives ~A$1.13 million R&D Tax Incentive

Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023

Oct 24, 2023, 8:00 AM EDT - 1 year ago

Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023

Immutep's Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer

Oct 23, 2023, 8:00 AM EDT - 1 year ago

Immutep's Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer

Immutep Announces Publication of Abstracts at ESMO Congress 2023

Oct 16, 2023, 8:00 AM EDT - 1 year ago

Immutep Announces Publication of Abstracts at ESMO Congress 2023

Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Oct 3, 2023, 8:00 AM EDT - 2 years ago

Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use

Sep 21, 2023, 8:00 AM EDT - 2 years ago

Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use

Immutep to Participate in September Investor Conferences

Sep 5, 2023, 9:00 AM EDT - 2 years ago

Immutep to Participate in September Investor Conferences

SeatownGreen
SeatownGreen Aug. 5 at 1:54 PM
$IMMP It’s always come down to the partnership Immutep consummates. There’s an exciting implication in this HNSCC single arm pathway discussed with FDA. It really applies to all 18 approved Keytruda indications with zero PD-L1 expression. Also applies to other PD-1/PD-L1 therapies, which are many. The development deal is where this has always been headed.
0 · Reply
brad97
brad97 Aug. 5 at 1:52 PM
$IMMP
0 · Reply
rispi
rispi Aug. 5 at 1:46 PM
$IMMP
0 · Reply
Nico07
Nico07 Aug. 5 at 1:33 PM
$IMMP The clue of the story is nobody knows 🫣 Let’s go Immutep
0 · Reply
gloryb
gloryb Aug. 5 at 12:57 PM
$IMMP well that was fun for 30 minutes
0 · Reply
MasterOfMyDomains
MasterOfMyDomains Aug. 5 at 12:10 PM
$IMMP https://www.stocktitan.net/news/IMMP/immutep-receives-positive-feedback-from-fda-on-late-stage-clinical-qk17pahwvxqx.html
0 · Reply
MasterOfMyDomains
MasterOfMyDomains Aug. 5 at 12:06 PM
$IMMP
0 · Reply
dbr_island
dbr_island Aug. 5 at 12:02 PM
$IMMP lnow VYNE very soon 🧨 Here’s why👇
0 · Reply
Stock_Catcher
Stock_Catcher Aug. 5 at 12:01 PM
$IMMP hits
0 · Reply
theinvestaar
theinvestaar Aug. 5 at 2:35 AM
$IMMP you don't even make sense what you're talking about. How many presentations do we have coming up at ESMO?
2 · Reply
ToRni27
ToRni27 Aug. 5 at 2:33 AM
$IMMP bad news. Phase 2b is not enough. They need to run a phase 3 trial for approval. If this goes up tomorrow you can easily swing trade it. It will dump; nothing achived yet. People know that another trial in cancer indication will take you 2-3 years at minimum. So the only catalyst is tacti 004 phase 3 in lung cancer left now. Data to be expected late 2026 / early 2027. Merck is the only company which could bring pressure on FDA, saying we need this upgrade to save more lifes. FDA will not listen to a small cap australian biotech but to a life saving Merck pharma company.
0 · Reply
ToRni27
ToRni27 Aug. 5 at 2:20 AM
$IMMP @TheIrishCzar still far away. FDA said they need a phase 3 trial. That takes another 2-3 years. Mr Voigt said they will focus on tacti 004 phase 3 cuz he knows that phase 3 will be finished sooner than a new phase 3 that will probably start in 6-9 months and run another 2 years for data. Its the typically biotech bullshyt.
0 · Reply
TheIrishCzar
TheIrishCzar Aug. 5 at 2:10 AM
$IMMP I think there is a good chance that Merck will pay for the small (79-90 patients) single arm option the FDA is offering. They get a new market and have more proved ground. Partnership news to follow?
0 · Reply
theinvestaar
theinvestaar Aug. 5 at 1:58 AM
$IMMP NSCLC is the key. This is gravy!!!!
0 · Reply
ToRni27
ToRni27 Aug. 5 at 1:57 AM
$IMMP Second, this means that FDA denied it. Cuz nothing is greater than approval. No matter the indication: "Our primary focus clearly remains the pivotal TACTI-004 Phase III“
0 · Reply
ToRni27
ToRni27 Aug. 5 at 1:57 AM
$IMMP This means no approval anytime soon. Sorry guys. „Paths for future clinical development and potential accelerated approval in light of the FDA's Project FrontRunner include a randomised registrational trial evaluating efti in combination with KEYTRUDA against standard-of-care therapy or alternatively a smaller single-arm study (e.g. 70 - 90 patients) with safety, response rate, and duration of response as key endpoints, followed by a confirmatory randomised study that builds on the existing data.“
0 · Reply
dgbio
dgbio Aug. 5 at 1:05 AM
$IMMP The ideal partnership would be with a company that does not have its own anti-PD-1 program. This would allow extensive development of efti in combination with various anti-PD-1 drugs across multiple indications.
1 · Reply
TheIrishCzar
TheIrishCzar Aug. 5 at 12:58 AM
$IMMP not accelerated approval.. yet, but dang close. They can a small trial to get it. A cheaper and quicker way to approval.
0 · Reply
TheIrishCzar
TheIrishCzar Aug. 5 at 12:57 AM
$IMMP https://app.sharelinktechnologies.com/announcement/asx/79a2f52415da02bb80ed293967f9bbed
0 · Reply
dgbio
dgbio Aug. 5 at 12:43 AM
$IMMP “Our primary focus clearly remains the pivotal TACTI-004 Phase III evaluating efti as first line therapy for non-small cell lung cancer and we are excited with its progress to date and the consistent, encouraging feedback we hear from physicians. This focus and additional considerations will be reviewed internally and discussed with stakeholders and potential strategic partners in regards to forward paths in head and neck cancer" If we discuss non-primary stuff with potential strategic partners, are we getting close to a deal?
1 · Reply
dgbio
dgbio Aug. 5 at 12:39 AM
$IMMP Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1 https://app.sharelinktechnologies.com/announcement/asx/79a2f52415da02bb80ed293967f9bbed
0 · Reply
theinvestaar
theinvestaar Aug. 5 at 12:37 AM
$IMMP I knew it!! News out!!
0 · Reply